Caplin Point Laboratories Ltd.

 
 The Company was incorporated on 16th April, 1990 under the  Act as a
 Private Limited Company under the name of CAPLIN POINT LABORATORIES
 PRIVATE LIMITED.  The name of the Company  was changed to CAPLIN
 POINT LABORATORIES LIMITED effective 23rd April 1993.  The Company
 has adopted a new set of Articles on 12th March, 1993 as applicable
 to public limited companies.
 
 The Company was incorporated as an extension of a pharmaceutical
 manufacturing unit started by M/s Triwin Pharmaceuticals, the first
 pharmaceutical venture started by Mr. P C Partheeban (presently the
 Managing Director), Mr. T Palanisamy and Mr. S Karunakaran in the
 year 1987 as a partnership firm.  In the year 1990, the Company was 
 incorporated by the partners of the aforesaid firm alongwith Mr. B A
 Ahmed.  Soon thereafter, Mr. S Jayaraman joined the Board to take
 charge of production.  
 
 Recently, the Board has been recast with all Directors except
 Mr.P.C.Partheeban making room for broadbasing the Board.  The
 resigning Directors have taken positions as Senior level Managers in
 the Company.
 
 M/s Triwin Pharmaceuticals was engaged in the business of manufacture
 of Tablets, Liquid orals and Capsules (Non-Antibiotic) and Import
 Sales of family planning and certain life saving drugs.  The said
 firm also started the Export of manufactured formulations in the year
 1992-93.
 
 Even after the incorporation of the Company, the firm  continued its
 manufacturing, sales and export of Tablets, Liquid orals and Capsules
 (Non-Antibiotic) and business of import sales while the Company
 started the manufacture of Ointments, Oral Powders and Capsules
 (Antibiotic).
 
 The said firm has since been taken over by the Company with effect
 from 1st September, 1993 with the objective of consolidation of the
 business of the Company into a single larger entity for setting up
 the Project envisaged.  All the assets and liabilities of the firm
 were taken over at book values as at 31st August 1993.  The Company's
 turnover in 
 future shall comprise of the sales generated from the manufacturing
 faculties of the erstwhile firm also.  Salient terms of the takeover
 Agreement executed by the Company with M/s. Triwin Pharmacuticals
 ('Triwin') are as follows.
 
 a.  Transfer and vesting of assets and liabilities of Triwin in the
 Company 
 
 All the assets and liabilities of Triwin including its factory
 located at No. 44, Kamakoti Nagar Annexe,Valasaravakkam, Madras 600
 087, on going business basis are transferred at book values as on
 31st August 1993.
 
 b.  Net consideration for the transfer of assets and liabilities 
 
 Consideration payable by the Company shall be the net worth of Triwin
 (excluding good will) estimated at Rs.31,62,000 on the basis of its
 audited accounts as at 31st August 1993.
 
 c.  Continuance of Business 
 
 In the post-transfer stage, the Company to continue to do the
 business then carried on by Triwin (including the manufacturing
 operation) and Triwin shall suspend all the production/sales
 activities hitherto carried on by them.
 
 d.  Discharge of Purchase consideration 
 
 The Company to issue at par its Shares credited as fully paid-up to
 the partners of Triwin for an aggregate nominal value of Rs.
 31,62,000 (Rupees Thirty One lacs Sixty Two Thousand only) in the
 proportion of amounts lying to the credit of the respective
 capital/current accounts as on  31st August 1993.
 
 
 
 2010
 
 -Caplin Point Laboratories Ltd has recommended a final dividend of
 Re. 1/- per share (10%) 
 
 2011
 
 -Caplin Point Laboratories Ltd has Recommended a final Dividend of
 Re. 1.50 per share (15%)
 
 -Mr. Vivek Siddharth has been appointed as the Chief Operating
 Officer of the Company 
 
 2012
 
 -Caplin Point Laboratories Ltd has recommended dividend a final
 dividend of Rs. 2/- per share (20%) 
 
 -Mr. D. P. Mishra has been appointed as a Whole Time Director of the
 Company
 
 2013
 
 -Mr. Mohanraj has been appointed as the Vice President - Finance and
 Company Secretary of the company.
 
 2014
 
 -Caplin has commenced its additional line of Production in the area
 of Suppositories which is unique in its feature which very few Pharma
 Companies have.
 
 -Caplin Point Lab gets listing on Forbes Asia and rsquo;s ‘200
 Best Billion and rsquo; 2014.
 
 2015
 -Caplin Point Lab - Caplin Point gets EU GMP approval for Sterile
 Injectable Site
 -Caplin Point Lab - Caplin Point gets Brazil's Anvisa approval for
 Sterile Injectable Site
 
 2016
 
 -Caplin Point Lab - US FDA inspection completed at Caplin Point's
 Injectable site.
 
 2017
 
 -Caplin Point Laboratories received approval from the U.S. Food and
 Drug Administration (USFDA) of its Abbreviated New Drug Application
 (ANDA) for Ketorolac Tromethamine Injection 30mg/mL, a product
 developed for Cycle Pharmaceuticals. 
 
 -Caplin Point gets USFDA nod for Ketorolac Tromethamine Injection.
 
 2018
 
 -USFDA completes inspection at Caplin Point Lab's sterile injectable
 facility in Tamil Nadu.
 
 2019
 
 -Caplin Point Laboratories partners with Baxter Corporation for
 injectable portfolio.
 
 -USFDA completes inspection at Caplin Steriles Injectable site.
 
 -Caplin Steriles gets USFDA nod for hemorrhage prevention drug.
 
 -Caplin Point Labs gets EIR from USFDA for injectable facility.
 
 2020
 
 -Caplin Point Laboratories Chairman C C Paarthipan said the company
 has partnered with Xellia which has a long standing track record of
 commercial success in the US for injectable products. 
 
 -Caplin Point Laboratories received the final approval from the US
 drug regulator for its Abbreviated New Drug Application (ANDA)
 Phenylephrine Hydrochloride injection. 
 
 -Caplin Point Laboratories Ltd -Caplin Steriles Gets USFDA Approval
 For Verapamil Hydrochloride Injection USP
 
 2021
 
 -Caplin Point arm inks strategic partnership with Canada's JAMP
 Pharma Group.
 
 -Caplin Point Laboratories arm gets USFDA nod for Neostigmine
 Methylsulfate Injection.
 
 2023
 
 - Lifetime Achievement Award 2023-Business
 
 - Forbes Asia Best Under Billion Award 2023